Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2011

Open Access 01-12-2011 | Review

Non-Invasive markers for hepatic fibrosis

Authors: Ancha Baranova, Priyanka Lal, Aybike Birerdinc, Zobair M Younossi

Published in: BMC Gastroenterology | Issue 1/2011

Login to get access

Abstract

With great advancements in the therapeutic modalities used for the treatment of chronic liver diseases, the accurate assessment of liver fibrosis is a vital need for successful individualized management of disease activity in patients. The lack of accurate, reproducible and easily applied methods for fibrosis assessment has been the major limitation in both the clinical management and for research in liver diseases. However, the problem of the development of biomarkers capable of non-invasive staging of fibrosis in the liver is difficult due to the fact that the process of fibrogenesis is a component of the normal healing response to injury, invasion by pathogens, and many other etiologic factors. Current non-invasive methods range from serum biomarker assays to advanced imaging techniques such as transient elastography and magnetic resonance imaging (MRI). Among non-invasive methods that gain strongest clinical foothold are FibroScan elastometry and serum-based APRI and FibroTest. There are many other tests that are not yet widely validated, but are none the less, promising. The rate of adoption of non-invasive diagnostic tests for liver fibrosis differs from country to country, but remains limited. At the present time, use of non-invasive procedures could be recommended as pre-screening that may allow physicians to narrow down the patients' population before definitive testing of liver fibrosis by biopsy of the liver. This review provides a systematic overview of these techniques, as well as both direct and indirect biomarkers based approaches used to stage fibrosis and covers recent developments in this rapidly advancing area.
Appendix
Available only for authorised users
Literature
1.
Schiff ER, Lee SS, Chao YC, Kew-Yoon S, Bessone F, Wu SS, Kryczka W, Lurie Y, Gadano A, Kitis G, Beebe S, Xu D, Tang H, Iloeje U: Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2010,
2.
Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B: Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010, 52 (3): 886-893. 10.1002/hep.23785.PubMed
3.
Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, Jones DE, Burt AD, Kirby JA: Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest. 2008, 88: 112-123. 10.1038/labinvest.3700704.PubMed
4.
Brenner DA: Molecular pathogenesis of liver fibrosis. Transactions of the American Clinical and Climatological Association. 2009, 120: 361-368.PubMedPubMedCentral
5.
Malhi H, Guicciardi ME, Gregory J, Gores GJ: Hepatocyte death: a clear and present danger. Physiol Rev. 2010, 90: 1165-1194. 10.1152/physrev.00061.2009.PubMedPubMedCentral
6.
Roberts RA, Ganey PE, Ju C, Kamendulis LM, Rusyn I, Klaunig JE: Role of the Kupffer Cell in Mediating Hepatic Toxicity and Carcinogenesis. Toxicological Sciences. 2006, 96 (1): 2-7. 10.1093/toxsci/kfl173. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008, 88(1): 125-172PubMed
7.
Jiao J, Friedman SL, Aloman C: Hepatic fibrosis. Curr Opin Gastroenterol. 2009, 25 (3): 223-229. 10.1097/MOG.0b013e3283279668.PubMedPubMedCentral
8.
9.
Fontana L, Jerez D, Rojas-Valencia L, Solis-Herruzo JA, Greenwel P, Rojkind M: Ethanol induces the expression of alpha1(I) procollagen mRNA in a co-culture system containing a liver stellate cell-line and freshly isolated hepatocytes. Biochim Biophys Acta. 1997, 1362: 135-144.PubMed
10.
Purohit V, Brenner DA: Mechanisms of Alcohol-Induced Hepatic Fibrosis: A Summary of the Ron Thurman Symposium. Hepatology. 2006, 43 (4): 872-878. 10.1002/hep.21107.PubMed
11.
Bertolani C, Marra F: The role of adipokines in liver fibrosis. Pathophysiology. 2008, 15: 91-101. 10.1016/j.pathophys.2008.05.001.PubMed
12.
Diehl AM: Nonalcoholic steatosis and steatohepatitis, Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol. 2002, 282: G1-G5.PubMed
13.
Rahmouni K, Haynes WG: Endothelial effects of leptin: implications in health and diseases. Curr Diab Rep. 2005, 5: 260-266. 10.1007/s11892-005-0020-5.PubMed
14.
Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, Mazzinghi B, Romagnani P, Milani S, Gines P, Colmenero J, Parola M, Gelmini S, Tarquini R, Laffi G, Pinzani M, Marra F: Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol. 2006, 169: 2042-2053. 10.2353/ajpath.2006.060081.PubMedPubMedCentral
15.
Glaser SS, Gaudio E, Miller T, Alvaro D, Alpini G: Cholangiocyte proliferation and liver fibrosis. Expert Rev Mol Med. 2009, 25; 11: e7-
16.
Bataller R, Yang L, Brenner DA: A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology. 2004, 40: 1151-1159. 10.1002/hep.20427.PubMed
17.
Martin-Vílchez S, Sanz-Cameno P, Rodriguez-Munoz Y, Majano PL, Molina-Jimenez F, Lopez-Cabrera M, Moreno-Otero R, Lara-Pezzi E: The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells. Hepatology. 2008, 47 (6): 1872-1883. 10.1002/hep.22265.PubMed
18.
Lin W, Wu G, Li S, Weinberg EM, Kumthip K, Peng LF, Mendez-Navarro J, Chen WC, Jilg N, Zhao H, Goto K, Zhang L, Brockman MA, Schuppan D, Chung RT: HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NF{kappa}B. J Biol Chem. 2010,
19.
Sebastiani G, Alberti A: Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol. 2006, 12 (23): 3682-3694.PubMedPubMedCentral
20.
West J, Card TR: Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology. 2010, 139 (4): 1230-7. 10.1053/j.gastro.2010.06.015. Epub 2010 Jun 12PubMed
21.
Terjung B, Lemnitzer I, Dumoulin FL, Effenberger W, Brackmann HH, Sauerbruch T, Spengler U: Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion. 2003, 67 (3): 138-45.PubMed
22.
Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981, 1: 431-435. 10.1002/hep.1840010511.PubMed
23.
Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP: An appraisal of the histopathological assessment of liver fibrosis. Gut. 2006, 55: 569-578. 10.1136/gut.2005.084475.PubMedPubMedCentral
24.
Scheuer PJ: Classification of chronic viral hepatitis: a need for reassessment. Journal of Hepatology. 1991, 13: 372-4. 10.1016/0168-8278(91)90084-O.PubMed
25.
Desmet V J, Gerber M, Hoofnagle JH, et al: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology. 1994, 19: 1513-20. 10.1002/hep.1840190629.PubMed
26.
Ratnakar KS, Sudha S: Image analysis in the evaluation of chronic hepatitis. Bahrain Medical Bulletin. 2001
27.
Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996, 24 (2): 289-293.
28.
Poynard T, Hepatitis B, Hepatitis C: management and treatment. A Martin Dunitz Book. 2002, Taylor & Francis, United Kingdom, 1
29.
Franciscus A: HCV Diagnostic tools: Grading and staging a liver biopsy. 2010, HCSP, Version 2.4
30.
Poynard T, Ratziu V, Benmanov Y, Martino VD, Bedossa P, Opolon P: Fibrosis in patients with hepatitis C: Detection and significance. Semin Liver Dis. 2000, 20 (1): 0047-0056. 10.1055/s-2000-9258.
31.
Bedossa P, Carrat F: Liver fibrosis: screening is not staging. J Hepatol. 2009, 50 (6): 1268-1269. 10.1016/j.jhep.2009.02.011.PubMed
32.
Bondini S, Kleiner DE, Goodman ZD, Gramlich T, Younossi ZM: Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis. 2007, 11 (1): 17-23. 10.1016/j.cld.2007.02.002. viiPubMed
33.
Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, Benhamou Y, Bourlière M, de Ledinghen V, FibroPaca Group: Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem. 2007, 53 (9): 1615-22. 10.1373/clinchem.2007.085795.PubMed
34.
Bedossa P, Dargère D, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003, 38 (6): 1449-57.PubMed
35.
Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005, 41 (1): 48-54. 10.1002/hep.20506.PubMed
36.
Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E: Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008, 134 (4): 960-74. 10.1053/j.gastro.2008.01.034.PubMed
37.
Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, Bedossa P, FIBROSTIC study group: Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010, 53 (6): 1013-21. 10.1016/j.jhep.2010.05.035.PubMed
38.
Fraquelli M, Rigamonti C, Casazza G, Donato MF, Ronchi G, Conte D, Rumi M, Lampertico P, Colombo M: Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol. 2011, 54 (4): 621-8. 10.1016/j.jhep.2010.07.017.PubMed
39.
Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005, 128 (2): 343-50. 10.1053/j.gastro.2004.11.018.PubMed
40.
Castéra L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, Couzigou P, de Lédinghen V: Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010, 51 (3): 828-35.PubMed
41.
Manning DS, Afdhal NH: Diagnosis and quantitation of fibrosis. Gastroenterology 2008, 134. Gastroenterology. 2008, 134 (6): 1670-1681. 10.1053/j.gastro.2008.03.001.PubMed
42.
Talwalkar JA: Antifibrotic therapies--emerging biomarkers as treatment end points. Nat Rev Gastroenterol Hepatol. 2010, 7 (1): 59-61. 10.1038/nrgastro.2009.197.PubMed
43.
Takahashi H, Ono N, Eguchi Y, Eguchi T, Kitajima Y, Kawaguchi Y, Nakashita S, Ozaki I, Mizuta T, Toda S, Kudo S, Miyoshi A, Miyazaki K, Fujimoto K: Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int. 2010, 30 (4): 538-45. 10.1111/j.1478-3231.2009.02130.x.PubMed
44.
Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K, Saito S, Nakajima A: Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse lastography. Radiology. 2010, 256 (2): 640-7. 10.1148/radiol.10091662.PubMed
45.
Rifai K, Cornberg J, Mederacke I, Bahr MJ, Wedemeyer H, Malinski P, Bantel H, Boozari B, Potthoff A, Manns MP, Gebel M: Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). Dig Liver Dis. 2011
46.
Kuroda H, Kakisaka K, Tatemichi Y, Sawara K, Miyamoto Y, Oikawa K, Miyasaka A, Takikawa Y, Masuda T, Suzuki K: Non-invasive evaluation of liver fibrosis using acoustic radiation force impulse imaging in chronic hepatitis patients with hepatitis C virus infection. Hepatogastroenterology. 2010, 57 (102-103): 1203-7.PubMed
47.
Taouli B, Ehman RL, Reeder SB: Advanced MRI methods for assessment of chronic liver disease. AJR. 2009, 193: 14-27. 10.2214/AJR.09.2601.PubMedPubMedCentral
48.
Rouviere O, Yin M, Dresner MA, Rossman PJ, Burgart LJ, Fidler JL, Ehman RL: MR elastography of the liver: preliminary results. Radiology. 2006, 240 (2): 440-448. 10.1148/radiol.2402050606.PubMed
49.
Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, Fidler JL, Ehman RL, Yin, M: Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol. 2007, 5: 1207-1213. 10.1016/j.cgh.2007.06.012.PubMedPubMedCentral
50.
Huwart L, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E, Peeters F, ter Beek LC, Rahier J, Sinkus R, Horsmans Y, Van Beers BE: Magnetic resonance elastography for the non invasive staging of liver fibrosis. Gastroenterology. 2008, 135 (1): 32-40. 10.1053/j.gastro.2008.03.076.PubMed
51.
Zhou K, Lu LG: Assessment of fibrosis in chronic liver diseases. Journal of Digestive Diseases. 2009, 10 (1): 7-14. 10.1111/j.1751-2980.2008.00356.x.PubMed
52.
Park SH, Kim CH, Kim DJ, Suk KT, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB: Usefulness of multiple biomarkers for the prediction of significant fibrosis in chronic hepatitis B. J Clin Gastroenterol. 2011, 45 (4): 361-5. 10.1097/MCG.0b013e31820d3458.PubMed
53.
Grigorescu M: Noninvasive Biochemical Markers of Liver Fibrosis. J Gastrointestin Liver Dis. 2006, 15 (2): 149-159.PubMed
54.
Gressner OA, Weiskirchen R, Gressner AM: Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver dependent malfunction tests. Clin Chim Acta. 2007, 381: 107-113. 10.1016/j.cca.2007.02.038.PubMed
55.
Veidal SS, Vassiliadis E, Bay-Jensen AC, Tougas G, Vainer B, Karsdal MA: Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair. 2010, 3 (1): 5-10.1186/1755-1536-3-5.PubMedPubMedCentral
56.
Lieber CS, Weiss DG, Paronetto F, Veterans Affairs Cooperative Study 391 Group: Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res. 2008, 32 (6): 1031-9. 10.1111/j.1530-0277.2008.00664.x.PubMed
57.
Jarcuska P, Janicko M, Veseliny E, Jarcuska P, Skladany L: Circulating markers of liver fibrosis progression. Clinica Chimica Acta. 2010, 411 (15-16): 1009-1017. 10.1016/j.cca.2010.04.009.
58.
Sun J: Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. Journal of Signal Transduction. 2010, 2010: 1-7.
59.
Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, Sato H, Seiki M, Watanabe A: Dual expression of matrix protease -2 and membrane type I-matrix proteinase in fibrotic human livers. Hepatology. 1997, 26: 1521-1529. 10.1002/hep.510260620.PubMed
60.
Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ: Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as non invasive markers of liver disease inchronic hepatitis C: comparison using ROC analysis. Dig Dis Sci. 1999, 44: 624-630. 10.1023/A:1026630129025.PubMed
61.
Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H: Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol. 1999, 14: 138-145.PubMed
62.
Hayasaka A, Suzuki N, Fujimoto N, et al: Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology. 1996, 24: 1058-1062. 10.1002/hep.510240513.PubMed
63.
Badra G, Lotfy M, El-Refaie A, Obada M, Abdelmonem E, Kandeel S, Fathy A: Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. Acta Microbiol Immunol Hung. 2010, 57 (1): 29-42. 10.1556/AMicr.57.2010.1.3.PubMed
64.
Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G, Dienes HP, Lohse AW: Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat. 2001, 8 (6): 430-7. 10.1046/j.1365-2893.2001.00314.x.PubMed
65.
Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I: Non-invasive markers to predict the liver fibrosis in non alcoholic fatty liver disease. Liver Int. 2006, 26: 864-871. 10.1111/j.1478-3231.2006.01312.x.PubMed
66.
Tran A, Benzaken S, Saint-Paul MC, Guzman-Granier E, Hastier P, Pradier C, Barjoan EM, Demuth N, Longo F, Rampal P: Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol. 2000, 12 (9): 989-993. 10.1097/00042737-200012090-00004.PubMed
67.
Berres ML, Papen S, Pauels K, Schmitz P, Zaldivar MM, Hellerbrand C, Mueller T, Berg T, Weiskirchen R, Trautwein C, Wasmuth HE: A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol. 2009, 50 (2): 370-6. 10.1016/j.jhep.2008.09.016.PubMed
68.
Kropf J, Gressner AM, Negwer A: Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases. Clinical Chemistry. 1988, 34: 2026-2030.PubMed
69.
Korner T, Kropf J, Gressner AM: Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol. 1996, 25: 684-688. 10.1016/S0168-8278(96)80239-X.PubMed
70.
Gressner OA, Gressner AM: Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int. 2008, 28: 1065-1079. 10.1111/j.1478-3231.2008.01826.x.PubMed
71.
Camps J, Marsillach J, Joven J: Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World J Gastroenterol. 2009, 15 (16): 1929-1933. 10.3748/wjg.15.1929.PubMedPubMedCentral
72.
Ferre N, Camps J, Prats E, Vilella E, Paul A, Figuera L, Joven J: Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem. 2002, 48 (2): 261-268.PubMed
73.
Molleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M, Friedman SL, Tornoe I, Schlosser A, Kloppel G, Schmiegel W, Meyer HE, Holmskov U, Stühler K: Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology. 2009, 49 (4): 1257-1266. 10.1002/hep.22764.PubMedPubMedCentral
74.
Haukeland JW, Schreiner LT, Lorgen I, Frigstad SO, Bang C, Raknerud N, Konopski Z: AST/ALT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis. Scand J Gastroenterol. 2008, 43 (10): 1241-1248. 10.1080/00365520802158614.PubMed
75.
Giboney PT: Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician. 2005, 71 (6): 1105-1110.PubMed
76.
Nguyen-Khac E, Chatelain D, Tramier B, Decrombecque C, Robert B, Joly JP, Brevet M, Grignon P, Lion S, Le Page L, Dupas JL: Assessment of asymptomatic liver fibrosis in alcoholic patients using FibroScan: prospective comparison with seven non-invasive laboratory tests. Aliment Pharmacol Ther. 2008, 28 (10): 1188-98. 10.1111/j.1365-2036.2008.03831.x.PubMed
77.
Lu LG, Zeng MD, Mao YM, Li JQ, Qiu DK, Fang JY, Cao AP, Wan MB, Li CZ, Ye J, Cai X, Chen CW, Wang JY, Wu SM, Zhu JS, Zhou XQ: Relationship between clinical and pathologic findings in patients with chronic liver diseases. World J Gastroenterol. 2003, 9 (12): 2796-2800.PubMedPubMedCentral
78.
DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re V: Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis. 2010, 10: 116-10.1186/1471-2334-10-116.PubMedPubMedCentral
79.
Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY: Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011, 53 (3): 726-36. 10.1002/hep.24105.PubMed
80.
Rossi E, Adams LA, Bulsara M, Jeffrey GP: Assessing liver fibrosis with serum marker models. Clin Biochem Rev. 2007, 28 (1): 3-10.PubMedPubMedCentral
81.
Guechot J, Lasnier E, Sturm N, Paris A, Zarski JP, ANRS HC EP 23 Fibrostar study group: Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta. 2010, 411 (1-2): 86-91. 10.1016/j.cca.2009.10.011.PubMed
82.
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M, APRICOT Clinical Investigators: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006, 43: 1317-1325. 10.1002/hep.21178.PubMed
83.
Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S: FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007, 46 (1): 32-36. 10.1002/hep.21669.PubMed
84.
Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, Moore RE, Afdhal NH: Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. J Hepatology. 2005, 43 (1): 78-84. 10.1016/j.jhep.2005.02.025.
85.
Braden B, Faust D, Sarrazin U, Zeuzem S, Dietrich CF, Caspary WF, Sarrazin C: 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2005, 21 (2): 179-85. 10.1111/j.1365-2036.2005.02317.x.PubMed
86.
Lalazar G, Pappo O, Hershcovici T, Hadjaj T, Shubi M, Ohana H, Hemed N, Ilan Y: A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT. J Viral Hepat. 2008, 15 (10): 716-728. 10.1111/j.1365-2893.2008.01007.x.PubMedPubMedCentral
87.
Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, Pawlotsky JM, McHutchison JG: Evaluation of a panel of non-invasive serum markers to differentiate mild from moderateto- advanced liver fibrosis in chronc hepatitis C patients. J Hepatol. 2004, 41: 935-942. 10.1016/j.jhep.2004.08.008.PubMed
88.
Patel K, Nelson DR, Rockey DC, Afdhal NH, Smith KM, Oh E, Hettinger K, Vallee M, Dev A, Smith-Riggs M, McHutchison JG: Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol. 2008, 6 (2): 242-247. 10.1016/j.cgh.2007.11.009.PubMed
89.
Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan G, Speers D, Jeffrey G: FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Validation of the Clin Chem. 2003, 49 (3): 450-454.PubMed
90.
Imbert-Bismut F, Messous D, Thibault V, Myers RB, Piton A, Thabut D, Devers L, Hainque B, Mercadier A, Poynard T: Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med. 2004, 42 (3): 323-333. 10.1515/CCLM.2004.058.PubMed
91.
Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C: Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterology. 2010, 10: 103-10.1186/1471-230X-10-103.PubMedPubMedCentral
92.
Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y: FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology. 2007, 45: 297-306. 10.1002/hep.21520.PubMed
93.
Sebastiani G, Vario A, Guido M, Alberti A: Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat. 2008, 15 (3): 212-218.PubMed
94.
Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, et al: Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol. 1998, 28: 439-446. 10.1016/S0168-8278(98)80318-8.PubMed
95.
Cales P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet MC, Dib N, Moal V, Macchi L, Chevailler A, Michalak S, Hunault G, Chaigneau J, Sawadogo A, Lunel F: FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol. 2008, 32 (6 Suppl 1): 40-51.PubMed
96.
Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007, 45: 846-854. 10.1002/hep.21496.PubMed
97.
Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ, European Liver Fibrosis Group: Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004, 127: 1704-1713. 10.1053/j.gastro.2004.08.052.PubMed
98.
Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM: Non-invasive markers of fibrosis in non-alcoholic fatty liver disease: validating the European Liver Fibrosis panel and exploring simple markers. Hepatology. 2008, 47 (2): 455-460.PubMed
99.
Callewaert N, Vlierberghe HV, Hecke AV, Laroy W, Delanghe J, Contreras R: Non invasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nature Medicine. 2004, 10: 429-434. 10.1038/nm1006.PubMed
100.
Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H: Alteration of protein glycosylation in liver diseases. J Hepatol. 2009, 50 (3): 592-603. 10.1016/j.jhep.2008.12.010.PubMed
101.
Younossi ZM, Baranova A, Stepanova M, Page S, Calvert VS, Afendy A, Goodman Z, Chandhoke V, Liotta L, Petricoin E: Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis. J Proteome Res. 2010, 9 (6): 3218-24. 10.1021/pr100069e.PubMed
102.
Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, Ferrari A, Alberti A: Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol. 2006, 44 (4): 686-93. 10.1016/j.jhep.2006.01.007.PubMed
103.
Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Guido M, Bourliere M, Noventa F, Alberti A: SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology. 2009, 49 (6): 1821-7. 10.1002/hep.22859.PubMed
Metadata
Title
Non-Invasive markers for hepatic fibrosis
Authors
Ancha Baranova
Priyanka Lal
Aybike Birerdinc
Zobair M Younossi
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2011
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-11-91

Other articles of this Issue 1/2011

BMC Gastroenterology 1/2011 Go to the issue

Research article

Discrimination of individuals in a general population at high-risk for alcoholic and non-alcoholic fatty liver disease based on liver stiffness: a cross section study

Research article

Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis

Research article

Gastronet survey on the use of one- or two-person technique for colonoscopy insertion

Research article

In vivo and ex vivo effects of propofol on myocardial performance in rats with obstructive jaundice

Research article

The addition of a pH-sensitive gel improves microemulsion stability for the targeted removal of colonic ammonia

Research article

Determinants of polyp Size in patients undergoing screening colonoscopy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits